(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
Medicinova's earnings in 2025 is -$12,010,330.On average, 4 Wall Street analysts forecast MNOV's earnings for 2025 to be -$20,010,868, with the lowest MNOV earnings forecast at -$24,032,661, and the highest MNOV earnings forecast at -$15,449,567. On average, 4 Wall Street analysts forecast MNOV's earnings for 2026 to be -$17,759,646, with the lowest MNOV earnings forecast at -$18,264,822, and the highest MNOV earnings forecast at -$16,994,524.
In 2027, MNOV is forecast to generate -$20,010,868 in earnings, with the lowest earnings forecast at -$19,226,128 and the highest earnings forecast at -$20,599,423.